Skip to main content

Table 1 Frequency of RET biomarkers in vandetanib Phase III NSCLC trial program

From: A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Clinical study RET biomarker, n (%) [95% CI]
RETrearrangement RETamplification LowRETgene copy number gain RET expression
Van Comp Van Comp Van Comp Van Comp
ZODIAC + ZEAL 1 2** 6 7 14 14 16 24
ZEPHYR 2 1 2 3 19 5 18 10
ZEST 0 1** 4 2 8 14 12 10
Untreated* 2 2 2
Non-Asian 5/632 (0.8) 19/632 (3.0) 49/632 (7.7) 52/756 (6.9)
[0.3–1.8] [1.8–4.6] [5.7–10.0] [5.2–8.9]
Asian 2/305 (0.7) 7/305 (2.3) 27/305 (8.8) 40/346 (11.6)
[0.1–2.3] [0.9–4.6] [5.9–12.5] [8.4–15.4]
Overall 7/937 (0.7) 26/937 (2.8) 76/937 (8.1) 92/1102 (8.3)
[0.3–1.5] [1.8–4.0] [6.4–10.0] [6.8–10.1]
  1. Comp, comparator; Van, vandetanib. *One patient randomized to ZODIAC and one randomized to ZEAL did not receive treatment. **One RET rearrangement with an unknown, non-KIF5B fusion partner was identified in the ZEAL comparator and one was identified in the ZEST comparator arm.